Atasoy Mehmet Mahir, Tasali Nuri, Çubuk Rahmi, Narin Burcu, Deveci Uğur, Yener Neşe, Çelik Levent
Department of Radiology, Maltepe University School of Medicine, Istanbul, Turkey.
Diagn Interv Radiol. 2015 Jan-Feb;21(1):22-7. doi: 10.5152/dir.2014.14139.
The aim of this study was to evaluate the 10-gauge vacuum-assisted stereotactic biopsy (VASB) of isolated Breast Imaging Reporting and Data System (BI-RADS) 4 microcalcifications, using histology and follow-up results.
From January 2011 to June 2013, VASB was performed on 132 lesions, and 66 microcalcification-only lesions of BI-RADS 4 were included into our study. VASB was performed using lateral decubitis stereotaxy for all patients. Pathologic results of VASB and further surgical biopsies were reviewed retrospectively. Patients who were diagnosed to have benign lesions by VASB were referred for follow-up. VASB and surgical histopathology results were compared to determine the underestimation ratios.
Fifteen out of 66 lesions from 63 patients (median age, 47 years; range, 34-88 years) were identified as malignant by VASB. Pathological results after surgery revealed three cases of invasive ductal carcinoma among the 12 VASB-diagnosed ductal carcinoma in situ (DCIS) lesions, for a DCIS underestimation rate of 25%. The atypical ductal hyperplasia underestimation rate was 0% for the three lesions. The follow-up period was at least 10 months, with an average of 22.7 months for all patients and 21.2 months for patients with VASB-diagnosed benign lesions. None of the patients had malignancy during the follow-ups. The false-negative rate was 0% in the follow-up of 48 patients.
VASB should be the standard method of choice for BI-RADS 4 microcalcifications. This method obviates the need for a surgical procedure in 73% of BI-RADS 4 microcalcification-only patients.
本研究旨在通过组织学检查和随访结果,评估10号真空辅助立体定向活检(VASB)对孤立性乳腺影像报告和数据系统(BI-RADS)4类微钙化灶的诊断价值。
2011年1月至2013年6月,对132个病灶进行了VASB检查,其中66个仅表现为微钙化灶且BI-RADS分类为4类的病灶纳入本研究。所有患者均采用侧卧位立体定向活检技术进行VASB。回顾性分析VASB及后续手术活检的病理结果。VASB诊断为良性病变的患者进行随访。比较VASB和手术组织病理学结果以确定低估率。
63例患者(中位年龄47岁;范围34 - 88岁)的66个病灶中,15个经VASB诊断为恶性病变。手术后病理结果显示,在VASB诊断为导管原位癌(DCIS)的12个病灶中有3例为浸润性导管癌,DCIS的低估率为25%。3个非典型导管增生病灶的低估率为0%。随访期至少10个月,所有患者平均随访22.7个月,VASB诊断为良性病变的患者平均随访21.2个月。随访期间所有患者均未发生恶性病变。48例患者随访的假阴性率为0%。
VASB应作为BI-RADS 4类微钙化灶的标准首选方法。该方法可使73%仅表现为BI-RADS 4类微钙化灶的患者无需接受手术。